drugset / Trial / NCT01664624
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
Timeline
- Start
- 2012-07
- Primary completion
- 2012-11
- Completion
- 2012-11
Outcome
Missed primary endpoint
registry Roflumilast + Alogliptin vs Alogliptin Alone; p = 0.388; LS Mean Difference -5.1 (95% CI -16.9 to 6.7); ANCOVA NCT01664624 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Comparator | Exenatide | Peptide | 5 ug | Subcutaneous |
| Subject | Roflumilast | Small molecule | 500 ug | Oral |